Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic Society International ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...